Norma Biln

Norma Biln has a comprehensive work experience spanning over several companies and roles. Norma began their career at Pfizer Pharmaceuticals in 1993 as a Clinical Research Associate and subsequently worked at Amgen as a Biopharmaceutical Specialist from 1997 to 2000. Norma then joined Abbott Laboratories as a District Manager from 2000 to 2004. In 2006, they became the Chief Executive Officer of Augurex Life Sciences Corp., a position they currently hold. Additionally, they serve as the Chair of the Board of Directors at BioTalent Canada from 2008 to 2017. In 2016, they assumed the role of Vice Chair on the Board of Directors at New Ventures BC and Lead Director on the Board of Directors at Resverlogix Corp. Norma also became the Director on the Board of Directors at BIOTECanada in 2018.

Norma Biln completed a Bachelor of Science degree in Physiology major at McGill University from 1989 to 1993. Following this, they pursued a Master of Business Administration (MBA) degree at the University of Phoenix from 1999 to 2001. Currently, Norma is a PhD candidate in Epidemiology at the School of Population and Public Health at The University of British Columbia, a program they have been enrolled in since 2018 and is expected to complete in 2023.